← The Wire
ANIPNasdaq
ANI PHARMACEUTICALS INC
Pharmaceutical Preparations · DE · CIK 1023024
Develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses
red 8-K · 90d
$1.86B
Market cap
$84.11
Last close
-0.5%
1D
+4.4%
5D
316K
Volume
Price · last 39 sessions+2.2%
May 4L $74.65 · H $84.63Jun 29
291
Total filings
May 21, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 21, 20268-KReg FD DisclosureMay 13, 202610-Q10-QMay 8, 20268-KResults of OperationsMay 8, 2026DEFA14ADEFA14AApr 9, 2026DEF 14ADEF 14AApr 9, 20268-KAuditor ChangeApr 7, 20268-KReg FD DisclosureMar 3, 202610-K10-KFeb 27, 20268-KResults of OperationsFeb 27, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KExecutive Change · Reg FD DisclosureDec 1, 20258-KResults of Operations · Reg FD DisclosureNov 10, 202510-Q10-QNov 7, 20258-KResults of OperationsNov 7, 20258-KEquity Issuance · Security-Holder RightsSep 26, 20258-KResults of Operations · Reg FD DisclosureSep 8, 202510-Q10-QAug 8, 20258-KResults of OperationsAug 8, 20258-KCompany UpdateJul 29, 20258-KCompany UpdateJul 23, 20258-KResults of Operations · Reg FD DisclosureJul 23, 20258-KResults of Operations · Reg FD DisclosureJun 4, 20258-KExecutive Change · Bylaw AmendmentMay 23, 20258-KResults of Operations · Reg FD DisclosureMay 20, 202510-Q10-QMay 9, 20258-KResults of OperationsMay 9, 2025DEFA14ADEFA14AMay 8, 20258-KCompany UpdateMay 8, 2025DEFA14ADEFA14AApr 10, 2025DEF 14ADEF 14AApr 10, 20258-KCompany UpdateMar 18, 20258-KCompany UpdateMar 14, 20258-KResults of Operations · Reg FD DisclosureMar 11, 202510-K10-KFeb 28, 20258-KResults of OperationsFeb 28, 20258-KResults of Operations · Reg FD DisclosureFeb 5, 20258-KResults of Operations · Reg FD DisclosureJan 13, 20258-KResults of Operations · Reg FD DisclosureNov 20, 202410-Q10-QNov 8, 20248-KResults of OperationsNov 8, 20248-KMaterial Agreement · Acquisition / DispositionSep 20, 20248-KCompany UpdateSep 16, 20248-KMaterial Agreement · Agreement TerminatedAug 13, 20248-KCompany UpdateAug 8, 20248-KCompany UpdateAug 7, 202410-Q10-QAug 6, 20248-KResults of OperationsAug 6, 20248-KMaterial Agreement · Reg FD DisclosureJun 24, 20248-KResults of Operations · Reg FD DisclosureJun 5, 20248-KExecutive Change · Shareholder VoteMay 23, 20248-KResults of Operations · Reg FD DisclosureMay 14, 202410-Q10-QMay 10, 20248-KResults of OperationsMay 10, 20248-KResults of Operations · Reg FD DisclosureApr 17, 2024DEFA14ADEFA14AApr 5, 2024DEF 14ADEF 14AApr 5, 20248-KResults of Operations · Reg FD DisclosureMar 12, 202410-K10-KFeb 29, 20248-KResults of OperationsFeb 29, 20248-KMaterial AgreementFeb 23, 2024SC 13GSCHEDULE 13GFeb 13, 2024SC 13GSC 13GFeb 12, 20248-KResults of Operations · Reg FD DisclosureFeb 8, 20248-KResults of Operations · Reg FD DisclosureJan 8, 20248-KResults of Operations · Reg FD DisclosureNov 15, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 8, 20238-KCompany UpdateOct 2, 20238-KResults of Operations · Reg FD DisclosureSep 25, 20238-KResults of Operations · Reg FD DisclosureSep 12, 20238-KResults of Operations · Reg FD DisclosureSep 7, 20238-KResults of Operations · Reg FD DisclosureAug 30, 20238-KExecutive ChangeAug 23, 202310-Q10-QAug 9, 20238-KResults of OperationsAug 9, 20238-KResults of Operations · Reg FD DisclosureJun 9, 20238-KExecutive Change · Shareholder VoteMay 25, 20238-KCompany UpdateMay 16, 2023424B5424B5May 12, 2023
Insider Activity
In the 90 days to Mar 13, 2026: 7 sold $4.2M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 3,162 | $71.64 | $227K |
| Mar 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $72.62 | $36K |
| Mar 11, 2026 | Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS | Sell | 4,772 | $74.91 | $357K |
| Mar 9, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 5,087 | $74.13 | $377K |
| Mar 9, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 3,602 | $74.18 | $267K |
| Mar 6, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 2,121 | $74.22 | $157K |
| Mar 6, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 1,485 | $75.00 | $111K |
| Mar 5, 2026 | Carey Stephen P.SVP & CFO | Sell | 4,000 | $75.56 | $302K |
| Mar 5, 2026 | Carey Stephen P.SVP & CFO | Sell | 3,312 | $75.42 | $250K |
| Mar 3, 2026 | Walsh Patrick DDirector | Sell | 6,000 | $74.23 | $445K |
| Mar 3, 2026 | Gutwerg OriSVP, GENERICS | Sell | 2,060 | $76.50 | $158K |
| Mar 2, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 417 | $74.00 | $31K |
| Feb 20, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415K |
| Feb 20, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 1,730 | $77.99 | $135K |
| Feb 19, 2026 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 2,084 | $77.53 | $162K |
| Feb 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $76.80 | $38K |
| Feb 12, 2026 | Mutz ChristopherHEAD OF RARE DISEASE | Sell | 7,032 | $76.55 | $538K |
| Jan 13, 2026 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42K |
| Dec 18, 2025 | Davis KristaSVP, CHIEF HR OFFICER | Sell | 1,622 | $82.40 | $134K |
| Dec 12, 2025 | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $82.32 | $33K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance